Compare BioArctic AB with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
SEK 29,348 Million (Small Cap)
28.00
NA
0.00%
-1.11
51.97%
14.92
Revenue and Profits:
Net Sales:
438 Million
(Quarterly Results - Mar 2026)
Net Profit:
212 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.94%
0%
-2.94%
6 Months
-3.25%
0%
-3.25%
1 Year
76.12%
0%
76.12%
2 Years
36.6%
0%
36.6%
3 Years
-3.91%
0%
-3.91%
4 Years
306.83%
0%
306.83%
5 Years
155.61%
0%
155.61%
BioArctic AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
100.08%
EBIT Growth (5y)
78.36%
EBIT to Interest (avg)
-8.97
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.28
Sales to Capital Employed (avg)
0.58
Tax Ratio
3.43%
Dividend Payout Ratio
17.32%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
17.86%
ROE (avg)
15.35%
Valuation key factors
Factor
Value
P/E Ratio
28
Industry P/E
Price to Book Value
14.36
EV to EBIT
19.05
EV to EBITDA
18.96
EV to Capital Employed
-125.55
EV to Sales
13.04
PEG Ratio
0.04
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
51.97%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 2 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
437.60
184.00
137.83%
Operating Profit (PBDIT) excl Other Income
214.40
37.80
467.20%
Interest
0.50
4.90
-89.80%
Exceptional Items
0.00
0.00
Consolidate Net Profit
212.40
-8.80
2,513.64%
Operating Profit Margin (Excl OI)
489.90%
188.40%
30.15%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 137.83% vs 38.03% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 2,513.64% vs 89.87% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,999.10
257.40
676.65%
Operating Profit (PBDIT) excl Other Income
1,396.20
-205.20
780.41%
Interest
2.40
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
1,022.30
-177.10
677.24%
Operating Profit Margin (Excl OI)
684.40%
-892.20%
157.66%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 676.65% vs -58.21% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 677.24% vs -177.27% in Dec 2024
About BioArctic AB 
BioArctic AB
Pharmaceuticals & Biotechnology
BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.
Company Coordinates 
Company Details
Warfvinges vag 35 , STOCKHOLM None : 112 51
Registrar Details






